OncoMatch/Clinical Trials/NCT04939090
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Is NCT04939090 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Olanzapine and Megestrol Acetate for advanced malignant solid neoplasm.
Treatment: Olanzapine · Megestrol Acetate — This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic adrenal steroids
Exception: short-term dexamethasone within 3 days of chemotherapy for control of chemotherapy side effects
Not currently using systemic adrenal steroids (with the exception of short-term dexamethasone within 3 days of chemotherapy for control of chemotherapy side effects)
Cannot have received: androgens
No use of androgens ... within the past month
Cannot have received: progesterone analogs
No use of ... progesterone analogs ... within the past month
Cannot have received: other appetite stimulants
No use of ... other appetite stimulants within the past month
Cannot have received: antipsychotic agent (olanzapine, risperidone, quetiapine, clozapine, butyrophenone)
Not currently using olanzapine for another medical condition or had previously used olanzapine for chronic nausea or for any pre-existing psychotic disorder; No treatment with another antipsychotic agent, such as risperidone, quetiapine, clozapine, butyrophenone within 30 days of enrollment
Cannot have received: tube feedings or parenteral nutrition
Not receiving ongoing tube feedings or parenteral nutrition at the time of registration
Lab requirements
Blood counts
Granulocytes > 1000/hpf
Kidney function
Serum creatinine <= 2.0 mg/dL
Liver function
AST or ALT <= 3 x upper limit of normal (ULN)
Serum creatinine <= 2.0 mg/dL; AST or ALT <= 3 x upper limit of normal (ULN); Granulocytes > 1000/hpf
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arizona Center for Cancer Care - Gilbert · Gilbert, Arizona
- CTCA at Western Regional Medical Center · Goodyear, Arizona
- Arizona Center for Cancer Care-Peoria · Peoria, Arizona
- Arizona Center for Cancer Care - Phoenix · Phoenix, Arizona
- Arizona Center for Cancer Care - Osborn · Scottsdale, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify